In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer and Lion Bioscience look for new drugs, diagnostics

Executive Summary

Bayer will collaborate with Heidelberg-based Lion Bioscience (sequencing and biocomputing services) in a five-year research agreement. Bayer will make precommmercial payments totaling up to $50-60mm, including an up-front equity investment, technology access fees, R&D money (estimated at $25-30mm), and set-up funds for a new subsidiary named Lion Bioscience Research Inc.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Joint Venture

Related Companies